EndoGastric Solutions, Inc. Unveils New Research Demonstrating the Benefits of Transoral Incisionless Fundoplication (TIF®) vs. Maximum PPI Therapy
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
REDWOOD CITY, Calif.--(BUSINESS WIRE)--EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for Gastroesophageal Reflux Disease (GERD), today announced the presentation of randomized controlled trial data and key educational activities taking place at Digestive Disease Week® (DDW) 2013, which runs from May 18 to 21, at the Orange County Convention Center in Orlando, Fla.
Help employers find you! Check out all the jobs and post your resume.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for Gastroesophageal Reflux Disease (GERD), today announced the presentation of randomized controlled trial data and key educational activities taking place at Digestive Disease Week® (DDW) 2013, which runs from May 18 to 21, at the Orange County Convention Center in Orlando, Fla.
Help employers find you! Check out all the jobs and post your resume.